Atlantic Cancer Consortium leadership and members share updates with the Network

On Thursday, October 24th, leadership and researchers from the Atlantic Cancer Consortium (ACC) presented their work to Network members as part of the MOHCCN seminar series.
This series, which is being held periodically throughout the year, features virtual talks from MOHCCN leadership, investigators and trainees from each region, providing a platform for MOHCCN members to share their ongoing work in precision oncology with the wider Network.
This event will be co-chaired by Christine Wu, a member of the MOHCCN Patient Working Group from Campbellville, ON, and Véronique LeBlanc, PhD, Program Manager and Scientific Writer, MOHCCN.
Watch the full video
Speakers
ACC consortium activities update
- Dr. Sherri Christian - Professor, Department of Biochemistry, Memorial University of Newfoundland; MOHCCN consortium lead (PR2C)
Biobank NL overview
- Daniel Loos - Coordinator, Biobank NL
THSD4: a novel mediator of immune exclusion and pembrolizumab response in breast cancer
- Olivia Walker - PhD candidate, Marcato lab, Department of Pathology, Faculty of Medicine, Dalhousie University
Related Team Member
-
Sherri
Consortium LeaderMOHCCN Steering CommitteeWorking Group Member
Christian
-
Regional Consortia
Atlantic Cancer Consortium
- Prince Edward Island
- New Brunswick
- Newfoundland and Labrador
- Nova Scotia
We have rallied our region’s leading cancer researchers, institutions and care facilities to unite around this vision to enhance inter-institutional and inter-provincial cancer research collaboration,...Read more
Related News
-
New study shows how comprehensive sequencing and molecular tumour boards can help put precision oncology into practice
Precision oncology is a promising approach for personalized cancer treatments. A new study from a Network-funded team demonstrates how it can be put into practice, and the challenges that remain to ma... -
Princess Margaret Cancer Consortium leadership and members share updates with the Network
The presentation was part of MOHCCN Seminar Series, which features virtual talks from MOHCCN research partner investigators and trainees, providing a platform for MOHCCN members to share their ongoing... -
New computational tool provides clues on how to target cancers with KMT2D mutations
A new study led by Dr. Marco Marra describes a strategy for identifying potential novel treatment targets in cancers driven by the loss of genes that are classified as tumour suppressors. -
New study highlights long-read sequencing applications in precision oncology
A team of researchers that includes Marathon of Hope Cancer Centres Network members demonstrate applications for long-read sequencing in precision oncology in a new study published in Cell Genomics.